Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469583 | 0.86 | RXFP1 (0.61) | RXFP1GLP1RPTH1RIL23R | |
| SCHEMBL14769532 | 0.83 | GLP1R (0.67) | RXFP1GLP1R | |
| SCHEMBL16509035 | 0.82 | NPBWR1 (0.61) | RXFP1GLP1RNPBWR1IL23R | |
| SCHEMBL16508984 | 0.82 | NPBWR1 (0.61) | RXFP1GLP1RNPBWR1IL23R | |
| SCHEMBL30038811 | 0.81 | RXFP1 (0.72) | RXFP1GLP1RPTH1RNPBWR1IL23R | |
| SCHEMBL29568300 | 0.81 | KISS1R (0.61) | RXFP1PTH1RNPBWR1 | |
| SCHEMBL29568099 | 0.81 | KISS1R (0.61) | RXFP1PTH1RNPBWR1 | |
| SCHEMBL30052890 | 0.81 | KISS1R (0.60) | RXFP1GLP1RPTH1RNPBWR1IL23R | |
| SCHEMBL30817659 | 0.81 | KISS1R (0.65) | — | |
| SCHEMBL30092970 | 0.80 | NPBWR1 (0.59) | RXFP1GLP1RPTH1RNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K19 | RXFP1 1360/4885GLP1R 246/4885PTH1R 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.